Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype

Leukemia

Volumn 27, Issue 4, 2013, Pages 925-931

  Rio Machin, A ^a,b   Ferreira, B I ^a,b   Henry, T ^c   Gomez Lopez G ^a   Agirre, X ^d   Alvarez, S ^a,b   Rodriguez Perales, S ^a,b   Prosper, F ^d   Calasanz, M J ^e   Martinez J ^f   Fonseca, R ^c   Cigudosa, J C ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c MAYO CLINIC   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

aneuploidy; chromosomal rearrangements; microRNA profile; trisomies

Indexed keywords

CYCLIN D; IMMUNOGLOBULIN; IMMUNOGLOBULIN H; MICRORNA; MICRORNA 24; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHROMOSOME TRANSLOCATION; DIPLOIDY; DOWN REGULATION; FEMALE; HUMAN; HYPERDIPLOID; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BASE SEQUENCE; BLOTTING, WESTERN; DIPLOIDY; DNA METHYLATION; DNA PRIMERS; DOWN-REGULATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MICRORNAS; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 84876124577     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.302     Document Type: Article

References (34)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
2. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
3. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20: 807-813.
4. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr. J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
5. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982-2989.
6. Largo C, Saez B, Alvarez S, Suela J, Ferreira B, Blesa D et al. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulinrelated chromosome translocations. Haematologica 2007; 92: 795-802.
7. Zhou Y, Barlogie B, Shaughnessy Jr. JD. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009; 23: 1941-1956.
8. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116: 2543-2553.
9. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25: 1026-1035.
10. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105: 12885-12890.
11. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114: e20-e26.
12. Pichiorri F, De Luca L, Aqeilan RI. MicroRNAs: new players in multiple myeloma. Front Genet 2: 22.
13. Vatsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O et al. OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus. Leuk Res 2009; 33: 1670-1677.
14. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007; 136: 565-573.
15. Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfo L, Rossi C et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 115: 3949-3959.
16. Vilas-Zornoza A, Agirre X, Martin-Palanco V, Martin-Subero JI, San Jose-Eneriz E, Garate L et al. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS One 6: e17012.
17. Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, Gonzalez-Garcia I et al. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica 2006; 91: 184-191.
18. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 2009; 4: e6986.
19. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 24: 629-637.
20. Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TR, Shaughnessy Jr J. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol 2004; 126: 72-76.
21. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
22. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell 2009; 35: 610-625.
23. Lerner M, Harada M, Loven J, Castro J, Davis Z, Oscier D et al. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 2009; 315: 2941-2952.
24. Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 154: 569-578.
25. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 12: 335-348.
26. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119: 2100-2105.
27. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
28. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 107: 7904-7909.
29. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737-2743.
30. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet 70: 87-99.
31. Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 155: 561-579.
32. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008; 111: 1603-1609.
33. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51: 881-890.
34. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 52: 60-70.